To the best of our knowledge, the biomarkers widely used in the clinic, including carcinoembryonic antigens (CEAs), CA-199, CA-242, and CA-50, have limited cholangiocarcinoma diagnostic and prognostic sensitivity and specify. The gene discussed is CEACAM5; the disease is cholangiocarcinoma.